This week in cardiology from heartwire

http://media.theheart.org/podcasts/Heartwire/Media/Episode205/audio_podcast_jul29_m.m4a For the week ending July 26, 2013, we discuss the following top cardiology news from heartwire: • Appropriate, but ignored? New echo study raises questions • Aspirin often added to warfarin in AF without CAD, despite bleeding risk • NO big deal: Two types of pulmonary hypertension respond to novel agent • Diovan data-manipulation scandal touches Novartis in Japan And also, in brief: • Fear, confusion among women resuming sexual activity post-MI • Echo screening in asymptomatic adults has no mortality benefit Join us for a comprehensive review of this week's most important cardiology news.

For the week ending December 7, 2012 we discuss the following top cardiology news from heartwire: • SCAI releases new consensus on "ad hoc" PCI • Heart-healthy diet additive to drug benefits in secondary prevention of CVD • Societies prepare interventionalists for new payment codes • Increased mortality with digoxin in AF • Warfarin for six months should be norm for bioprosthetic aortic valves And also, in brief: • Fitness boosts effects of statins

For the week ending August 2, 2013, we discuss the following top cardiology news from heartwire: • Statins protective against Parkinson's: More evidence • The debate over abandoning off-pump CABG surgery • Prasugrel 5 mg, clopidogrel similarly safe, effective in non-PCI elderly with ACS • Perioperative beta-blocker controversy begins again with new meta-analysis And also, in brief: • Canadian CVD research spending yields solid bang for the buck • ACE inhibitors may slow cognitive decline Join us for a comprehensive review of this week's most important cardiology news.

For the week ending July 19, 2013, we discuss the following top cardiology news from heartwire: • The COURAGE patients who crossed over: New insights • Two new analyses link dabigatran to MI risk • Beta-blockers in HF get bum rap for most "side effects," says study • Ten emerging uses for cardiac CT from SCCT 2013 And also, in brief: • "Caution" warranted if consuming artificial sweeteners • Obesity duration linked to atherosclerosis and its progression Join us for a comprehensive review of this week's most important cardiology news.

For the week ending July 12, 2013, we discuss the following top cardiology news from heartwire: • New PCI programs cost billions, fail to improve timely access • Olmesartan label change warns of potential for spruelike enteropathy • Factor Xa inhibitor antidotes: Evidence they work may be untestable in big trials • Adding sufficient sleep to four healthy habits further lowers CVD risk And also, in brief: • Telmisartan, valsartan lower risk of CVD complications in diabetics • Adverse events with statins uncommon, meta-analysis shows Join us for a comprehensive review of this week's most important cardiology news.

For the week ending July 5, 2013, we discuss the following top cardiology news from heartwire: • AMPLIFY: Apixaban in acute VTE as effective but safer than standard anticoagulation • RESPECT "device-in-place" analysis: Benefits of PFO closure? • CV risk and HbA1c: Search continues for key cut points, subgroups • Aggressive glucose control no benefit in CV surgery patients with T2D And also, in brief: • FDA refuses rivaroxaban stent-thrombosis indication for now • Could some "normal" BMIs reduce life expectancy? Join us for a comprehensive review of this week's most important cardiology news.

For the week ending June 28, 2013 we discuss the following top cardiology news from heartwire: • Kidney-injury analysis "reassuring" for high-potency statins in PROVE-IT, A to Z • Triple therapy for new-onset diabetes: A paradigm shift? • NIH says ATP 4, JNC 8 guidance out "in a matter of months" (with a twist) • Look AHEAD: No CVD benefit with lifestyle intervention in diabetics And also, in brief: • Could some "normal" BMIs reduce life expectancy? • Serelaxin for AHF gets "breakthrough-therapy" path through FDA Join us for a comprehensive review of this week's most important cardiology news.

For the week ending June 21, 2013 we discuss the following top cardiology news from heartwire: • New European hypertension guidelines released: Goal is less than 140 mm Hg for all • Saxagliptin falls short in CVD outcomes study, SAVOR-TIMI 53 • Tea and coffee lower blood pressure in large French registry • Revised ACC/AHA HF guidelines address aldosterone, device use, quality of life And also, in brief: • Dabigatran 110 mg similar in benefit to 150 mg in weighted analysis • Disappointing real-world results with renal denervation: BP reductions small with ABPM Join us for a comprehensive review of this week's most important cardiology news.

For the week ending June 14, 2013 we discuss the following top cardiology news from heartwire: • Aspirin unneeded with anticoagulation/clopidogrel after MI, PCI in AF • Vegetarian diet linked to longer life, less CVD mortality • FDA says again: Rosiglitazone does not up CV risk • New obesity drug, lorcaserin, in US pharmacies next week And also, in brief: • BMJ digs deep into diabetes drug, pancreatic-cancer debate • Kentucky cardiologist admits to healthcare fraud in stenting case Join us for a comprehensive review of this week's most important cardiology news.

For the week ending June 7, 2013 we discuss the following top cardiology news from heartwire: Coenzyme Q10 supplementation reduces HF admissions and improves survival: Q-SYMBIO Mediterranean diet slows atherosclerosis progression in PREDIMED New mineralocorticoid-receptor antagonist passes in phase 2 study Sparks fly within FDA over longstanding ARB-cancer controversy: WSJ And also, in brief: NSAID CV-event risk high overall, but predictable in individuals, says analysis Four healthy lifestyle behaviors lower risk of death, slow CAC progression Join us for a comprehensive review of this week's most important cardiology news.

For the week ending May 31, 2013 we discuss the following top cardiology news from heartwire: • Two studies address diabetes risks with statins—one good news, one so-so • Rivaroxaban approved for ACS secondary prevention in Europe • Vildagliptin in HF patients with diabetes meets echo end point, but questions remain • Girl trouble: Rising tide of STEMI in young women "clearly not acceptable" And also, in brief: • MRI evidence of plaque progression in aliskiren-treated patients • RIPCORD: FFR during diagnostic angio may radically alter treatment plans Join us for a comprehensive review of this week's most important cardiology news.

For the week ending May 24, 2013 we discuss the following top cardiology news from heartwire: • BP reductions with renal denervation durable to 30 months: SYMPLICITY HTN-2 • Dietary saturated fat has undeserved bad reputation, says review • SCAAR: Could cheap heparin replace pricy bivalirudin in PCI for non-STE-ACS? • Dabigatran "real-life" results suggest caution needed And also, in brief: • How low should you go? Experts debate latest salvo in the war on sodium • Never too old to get moving: Aerobic fitness lowers risk of death in elderly Join us for a comprehensive review of this week's most important cardiology news.

For the week ending May 17, 2013 we discuss the following top cardiology news from heartwire: • Hormone therapy associated with MI in male-to-female transsexuals • Few failures show up in Durata, Riata ST Optim defibrillator-lead analysis • No benefit of fish oil in high-risk patients • Long-term PROTECT-AF analysis: Watchman attains efficacy superiority over warfarin in AF And also, in brief: • Apixaban superior to warfarin across range of INR values, ARISTOTLE analysis • Oral anticoagulants less used in paroxysmal than persistent AF: NCDR data Join us for a comprehensive review of this week's most important cardiology news.

For the week ending May 10, 2013 we discuss the following top cardiology news from heartwire: • ESC issues "practical guide" to new oral anticoagulants in AF • FDA approves atorvastatin/ezetimibe combo tablet • Midei malpractice suit settled before hearing Midei's testimony • No advantages, more surgery, with MitraClip at four years: EVEREST II And also, in brief: • Lancet antitobacco series launches as ACC chides FDA inaction • Stopping dabigatran ups stroke risk: New boxed warning Join us for a comprehensive review of this week's most important cardiology news.

For the week ending May 3, 2013 we discuss the following top cardiology news from heartwire: • To [vitamin] D or not to D? That is the question • US cardiologists see incomes climb in changing healthcare climate • Intestinal flora again implicated in CAD; but this time, also CV events • FDA okays Kcentra to reverse anticoagulation, stop bleeding And also, in brief: • ESC supports renal denervation as an option for treating resistant hypertension • FDA limits use of heart-failure drug due to liver injury Join us for a comprehensive review of this week's most important cardiology news.